Application dates: 29 November 2018 to 03 April 2019
The Health Technology Assessment Programme is accepting stage 1 applications to their commissioned workstream for this primary research topic:
What is the clinical and cost-effectiveness of augmenting a cholinesterase inhibitor with memantine for people with dementia with Lewy bodies or Parkinson’s disease dementia?
The UK NIHR and the Australian National Health and Medical Research Council (NHMRC) are collaborating on this research priority and will consider joint funding for any collaborative research proposals submitted to this brief. Applications which include a research collaboration between UK and Australian institutions are most welcome. Please refer to the supplementary guidance for additional requirements related to NIHR/NHMRC collaborative applications. Applications from UK institutions without an Australian collaborative element are also welcome for consideration.
- Commissioning brief
- Commissioning brief background information
- Stage 1 application supporting information
- Stage 1 guidance notes
- Instructions for completing collaborative research proposals
The deadline for applications is 1pm, 3 April 2019.
Visit funding web page